

# NOW A POWERFUL NEW ALTERNATIVE FOR GENITAL HERPES

'Famvir' 250 mg Tablets

'Famvir' 125 mg Tablets

famciclovir

## Prescribing Information

**Presentations** 'Famvir Tiltab' 250 mg Tablets, PL 10592/0035, each containing 250 mg famciclovir.

21 tablets: £107.35, 15 tablets £76.68,

210 tablets: £1073.50. 'Famvir Tiltab'

125 mg Tablets, PL 10592/0055,

each containing 125 mg famciclovir.

10 tablets: £25.56.

**Uses** Treatment of herpes zoster (shingles) infections and acute genital herpes infections. Famciclovir is the oral form of penciclovir, converted in the body to this active antiviral moiety.

**Dosage and administration** *Herpes zoster (shingles) infection* Adults: One 250 mg tablet t.i.d. for 7 days.

Treatment should be initiated as early as possible in the course of the disease, promptly after diagnosis.

*First-episode genital herpes infections*

Adults: One 250 mg tablet three times

daily for 5 days. Initiation of treatment

is recommended as soon as possible

after onset of lesions. *Acute recurrent*

*genital herpes infections* Adults: One

125 mg tablet twice daily for 5 days.

Initiation of treatment is recommended

during the prodromal period or as

soon as possible after onset of lesions.

*Elderly:* As for adults unless renal

function impaired. *Renally impaired*

*and renally impaired on*

*haemodialysis:* Reduced clearance of

penciclovir related to reduced function;

see Data Sheet for dosage

modification. *Hepatically impaired:*

No dosage modification required in

well compensated hepatic impairment.

*Children:* Data currently insufficient on

safety and efficacy.

**Contra-indication** Known hypersensitivity

to famciclovir.

**Precautions** Care in impaired renal

function (see Data Sheet).

**Drug interactions** No clinically

significant pharmacokinetic

interactions identified. Probenecid and

other drugs affecting the kidney could

affect plasma levels of penciclovir.

**Use in pregnancy and lactation** Not to

be used during pregnancy or lactation

unless benefits outweigh risk. Oral

penciclovir excreted in breast milk of

lactating rats.

**Adverse reactions** Well tolerated in

human studies. Generally mild or

moderate headache and nausea

reported in clinical trials and occurring

at similar incidence to placebo.

**Overdosage** No acute overdosage

reported. Symptomatic and supportive

therapy as appropriate.

**Legal category** POM. 15.3.95.

Based on 'The Kiss,' Auguste Rodin, 1886.

**SB** **SmithKline Beecham**  
Pharmaceuticals  
**Healthy Alliance**  
partnership beyond prescription



Welwyn Garden City, Hertfordshire AL7 1EY


'Famvir' and 'Tiltab' are trade marks

©1995 SmithKline Beecham Pharmaceuticals

0395 FM:AD/5/120/GM

**'FAM**  
famciclovir  
**VIR**

AN IMPORTANT INNOVATION FROM  
SMITHKLINE BEECHAM ANTIVIRAL RESEARCH



# Current Opinion in INFECTIOUS DISEASES

Subscribe now and stay up-to-date

## KEEP UP-TO-DATE WITH CURRENT OPINION

- Every year it is the most reliable source of information in the field.
- Every year the whole field is covered in 6 bi-monthly issues, broken down into 13 subjects.
- Every year within each subject, all the latest developments, expert comment and opinion, and recommended reading are featured.
- Every year **Current Opinion in Infectious Diseases** is the only reference you need to keep fully informed.

## PRICES FOR ANNUAL SUBSCRIPTION

£79.95 - \$134.95 Personal

£169.95 - \$269.95 Institutional

£45 - \$55 Pre-reg doctors/Residents

Postage: £10 UK £15.75 Eur \$11 N Am \$37 S Am £25 RoW

## EDITORS

**RG Finch & VT Andriole**

## 1995 SECTIONS AND EDITORS

### February

SEXUALLY TRANSMITTED DISEASES AND URINARY TRACT INFECTIONS *AR Ronald*  
HIV INFECTION AND AIDS *JP Phair*

### April

RESPIRATORY INFECTIONS *M Woodhead*  
GENERALIZED INFECTIONS *AL Bisno*

### June

PATHOGENESIS AND IMMUNE RESPONSE  
*DL Stevens*  
PEDIATRIC AND NEONATAL INFECTIONS  
*M Radetsky*

### August

INFECTIONS OF THE IMMUNOCOMPROMISED HOST  
*HG Prentice & CC Kibbler*  
NOSOCOMIAL AND HOSPITAL-RELATED INFECTIONS  
*PJ Sanderson*  
SKIN AND SOFT-TISSUE INFECTIONS *S Ash*

### October

TROPICAL AND TRAVEL-ASSOCIATED DISEASES  
*DR Hill*  
GASTROINTESTINAL INFECTIONS *R Fekety*

### December

ANTIMICROBIAL AGENTS: BACTERIAL/FUNGAL  
*GP Bodey*  
ANTIMICROBIAL AGENTS: VIRAL/PARASITIC  
*PL Chiodini & RJ Whitley*

## TO SUBSCRIBE IN N & S AMERICA CONTACT:

Current Science Ltd, Suite 700, 400 Market Street,  
Philadelphia, PA 19106, USA.  
Tel: 215-574-2210, or Toll Free: 800-552-5866 (US only)  
Fax: 215-574-3533

## IN THE REST OF WORLD:


Current Science Ltd, Middlesex House,  
34-42 Cleveland Street, London W1P 6LB, UK.  
Tel: +44 (0) 171 323 0323, or Freephone: 0800 212530 (UK only)  
Fax: +44 (0) 171 636 6911

# How to do it even better!

The highly popular *How To Do It* series is a collection of expert advice on an enormous range of topics that doctors need to know about that are not necessarily covered in formal training.

All three volumes have now been completely updated, with new chapters, and a user friendly format where subjects are grouped into themes. Whether you want to chair a committee, improve your counselling skills with cancer patients, or even survive a formal dinner, your questions will be answered in these entertaining and practical guides.


A must for all doctors, from students through to the retired.



## How to Do It Volume 1

- Management ● Employment
- Counselling


ISBN 0 7279 0848 0 272 pages April 1995  
UK £12.95; Overseas £15.00  
(BMA members £11.95; £14.00)



## How to Do It Volume 2

- Examinations ● Academia
- Research and Communication

ISBN 0 7279 0895 2 240 pages April 1995  
UK £12.95; Overseas £15.00  
(BMA members £11.95; £14.00)



## How to Do It Volume 3

- Writing ● Publishing and Publicity
- Something Different

ISBN 0 7279 0896 0 264 pages April 1995  
UK £12.95; Overseas £15.00  
(BMA members £11.95; £14.00)

## Purchase the complete set at a reduced price!

ISBN 0 7279 0906 1 UK £34.95; Overseas £39.00 (BMA members £31.95; £36.00)

**BMJ**  
Publishing  
Group

How to write  
a paper

### Order Form

Available from: **BMJ Publishing Group, P.O. Box 295, London WC1H 9TE, (Tel: 0171 383 6185/6245), medical booksellers or the BMJ bookshop in BMA House**

Please send me \_\_\_\_\_ copy/ies of HOW TO DO IT VOLUME 1

Please send me \_\_\_\_\_ copy/ies of HOW TO DO IT VOLUME 2

Please send me \_\_\_\_\_ copy/ies of HOW TO DO IT VOLUME 3

Please send me \_\_\_\_\_ COMPLETE SET/S OF HOW TO DO IT

Please send me \_\_\_\_\_ copy/ies of HOW TO WRITE A PAPER

BMA Membership No. \_\_\_\_\_

Name \_\_\_\_\_  
(Print Clearly)

Address \_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_ Postcode \_\_\_\_\_

Cheque enclosed (made payable to British Medical Journal) £ \_\_\_\_\_

Debit my AMERICAN EXPRESS/VISA/MASTERCARD

Card No. \_\_\_\_\_ Exp \_\_\_\_\_

Signature \_\_\_\_\_

☐ Please send me a BMJ PUBLISHING GROUP CATALOGUE



On reflection,  
no other  
treatment  
looks so  
convenient

Many women with genital warts would welcome the convenience and dignity of treating themselves at home.

New Warticon Fem makes self-treatment practical by the simple inclusion of a mirror in every pack.

Proven to be effective<sup>1</sup> and well tolerated<sup>2</sup> when used in this way,

Warticon Fem is now a clear first choice treatment.

**ABBREVIATED PRESCRIBING INFORMATION Warticon, Warticon Fem:** Podophyllotoxin 0.5% w/v. **Presentation:** An acidic ethanolic solution of 0.5% w/v podophyllotoxin. **Uses:** For the topical treatment of condyloma acuminata affecting the penis or the female external genitalia. **Dosage and Administration:** The affected area should be thoroughly washed with soap and water, and dried prior to application. Using the applicator provided, the warts should be painted twice daily for 3 days. The treated area should be allowed to dry. If residual warts persist, this 3-day treatment may be repeated, at weekly intervals, if necessary, for a total of 4 weeks of treatment. The majority of patients will not require in excess of 30 loops for each application, however a maximum of 50 loops per application (equivalent to 250µl of Warticon Solution) may be applied. Where lesions are greater in area than 4cm<sup>2</sup>, it is recommended that treatment takes place under the direct supervision of medical staff. **Contra-Indications, Warnings, etc:** Open wounds following surgical procedures should not be treated with podophyllotoxin. Hypersensitivity to podophyllotoxin is a contra-indication. Avoid contact with the eyes. In the event of the preparation entering the eye, the eye should be thoroughly bathed in water. **Side effects:** Local irritation may occur on the second or third day of application associated with the start of wart necrosis. In the majority of cases the reactions are mild. Tenderness, smarting, erythema, superficial epithelial ulceration and balanoposthitis have been reported. Local irritation decreases after treatment. **Use in Pregnancy:** Do not use during pregnancy or lactation. **Overdosage:** There have been no reported overdoses with Warticon Solution. No specific antidote is known. Following accidental spillage, wash the skin well with soap and water. In the event of accidental ingestion give emetic or stomach washout. Treatment should be symptomatic and in severe oral overdose ensure the airway is clear and give fluids, check and correct electrolyte balance, monitor blood gases and liver function. Blood count should be monitored for at least five days. **Pharmaceutical Precautions:** Product should be stored at room temperature. **Legal Category:** POM. **Package Quantities:** Each bottle contains 3ml of Warticon Solution. Plastic applicators are also enclosed in each pack. Each loop will carry a volume of approximately 5µl Warticon Solution. Warticon Fem also contains a mirror to facilitate accurate application. **Basic NHS Cost:** Warticon 3ml £14.50, Warticon Fem 3ml £14.50. **Product Licence Number:** PL3863/0007 **Date of Preparation:** March 1994.

NEW  
**Warticon<sup>®</sup>**  
*fem*  
Podophyllotoxin 0.5% w/v

Clearly simple enough for  
self-application in female genital warts

**Perstorp Pharma** Further information is available from: Perstorp Pharma Ltd, Intec 2, Wade Road, Basingstoke, Hants RG24 8NE. Tel: 0256 477868.

**REFERENCES** 1. Baker D. A. et al. *Obstet Gynecol* 1990; 76: 656-9. 2. Kinghorn G. R. et al. 1993; In press.

and Warticon are registered trademarks.